Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 12:8:F1000 Faculty Rev-1629.
doi: 10.12688/f1000research.18039.1. eCollection 2019.

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

Mari Iwasaki  1 , Yasutada Akiba  1   2 , Jonathan D Kaunitz  1   3
Affiliations
Review

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

Mari Iwasaki et al. F1000Res. .

Abstract

Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Genetic ablation of this peptide and its receptors in mice also provides new insights into the contribution of VIP towards physiological signaling and the pathogenesis of related diseases. Here, we discuss the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Keywords: VIP; VPAC1; VPAC2; colitis; gastrointestinal; gastrointestinal motility; gastrointestinal secretion; gastrointestinal tract; mast cells; neuropeptide; vasoactive intestinal peptide; vasodilation; ​​​​​​​functional bowel syndromes.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Processing of prepro-VIP to VIP.
PHI, peptide histidine isoleucine; PHM, peptide histidine methionine; VIP, vasoactive intestinal peptide; VIP–GKR, VIP precursor containing the internal cleave-amidation site Gly–Lys–Arg.
Figure 2.
Figure 2.. Broad multiple functions of vasoactive intestinal peptide in various organs.
Number in parenthesis represents the corresponding reference number.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Said SI, Mutt V: Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217–8. 10.1126/science.169.3951.1217 - DOI - PubMed
    1. Gronenborn AM, Bovermann G, Clore GM: A 1H-NMR study of the solution conformation of secretin. Resonance assignment and secondary structure. FEBS Lett. 1987;215(1):88–94. 10.1016/0014-5793(87)80119-9 - DOI - PubMed
    1. Henning RJ, Sawmiller DR: Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001;49(1):27–37. 10.1016/s0008-6363(00)00229-7 - DOI - PubMed
    1. Said SI: Vasoactive intestinal peptide. J Endocrinol Invest. 1986;9(2):191–200. 10.1007/BF03348097 - DOI - PubMed
    1. Umetsu Y, Tenno T, Goda N, et al. : Structural difference of vasoactive intestinal peptide in two distinct membrane-mimicking environments. Biochim Biophys Acta. 2011;1814(5):724–30. 10.1016/j.bbapap.2011.03.009 - DOI - PubMed

Publication types

MeSH terms

Substances